10 Affordable Biotech Stocks to Buy Right Now
In this article, we will take a look at some of the most affordable biotech stocks that are currently offering attractive upside potential.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 23,888,888 | $162,683,327 | +11% | 1.46% |
| 2. | RA Capital Management Peter Kolchinsky | 23,555,648 | $160,413,963 | 1.39% | |
| 3. | Vestal Point Capital Ryan Wilder | 19,415,000 | $132,216,150 | +8% | 3.09% |
| 4. | Siren L.L.C. Raymond Debbane | 9,846,579 | $67,055,203 | +12% | 1.36% |
| 5. | Octagon Capital Advisors Ting Jia | 9,693,244 | $66,010,992 | +10% | 5.93% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.75 | 750,000 | $2,062,500.00 | 2,841,704 | 2025-05-30 | Filing | |
| $2.25 | 1,333,333 | $2,999,999.25 | 1,333,333 | 2024-06-27 | Filing | |
| $1.63 | 100,000 | $163,000.00 | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | $14,820,000.30 | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | $350,000.10 | 999,381 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.24 | 200,000 | $1,248,000.00 | 936,410 | 2026-07-10 | Filing | |
| $4.46 | 200,000 | $892,000.00 | 1,136,410 | 2026-04-10 | Filing | |
| $4.52 | 1,655 | $7,480.60 | 1,442,131 | 2026-02-04 | Filing | |
| $4.61 | 26,918 | $124,091.98 | 1,317,389 | 2026-01-26 | Filing | |
| $4.75 | 89,132 | $423,377.00 | 1,344,307 | 2026-01-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,713,118 | $154,676,334 | 0.01% | |
| 2. | 20,691,927 | $140,912,023 | 0% | |
| 3. | 16,487,479 | $112,279,731 | 0.01% | |
| 4. | 13,560,258 | $92,345,357 | 0.79% | |
| 5. | 13,336,413 | $90,820,969 | 0% |
News See All
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?
Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TSHA.
Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential. Taysha Gene Therapies, Inc.
15 Best Small Cap Stocks to Buy for 10x Potential
In this article, we will look at the 15 Best Small Cap Stocks to Buy for 10x Potential.
10 Best US Stocks Under $5 to Buy
In this article, we will be looking at the 10 Best US Stocks Under $5 to Buy.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2026 Earnings Call Transcript May 6, 2026Taysha Gene Therapies, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.1.
10 Best Small-Cap Biotech Stocks to Buy According to Hedge Funds
In this article, we will look at the 10 Best Small Cap Biotech Stocks to Buy According to Hedge Funds.
9 Best Healthcare Penny Stocks to Buy According to Hedge Funds
In this article, we look at the 9 Best Healthcare Penny Stocks to Buy According to Hedge Funds. Volatility in the equity market has been on another level in the first quarter of the year.
10 Best Multibagger Penny Stocks to Invest In
In this article, we explore the 10 Best Multibagger Penny Stocks to Invest In. Small-cap and penny stocks are often overlooked by Wall Street as they tend to be extremely volatile.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026Taysha Gene Therapies, Inc. beats earnings expectations.
Hedge Fund Resource Center